Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financi
Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myer
Speculation about a takeover play for Cytokinetics isn’t going away, with Amgen the latest company to be linked to the company and its highly-anticipated cardiovascular dr
Shares in US biotech Cytokinetics have popped after a report that its aficamten drug improved symptoms in people with a rare and progressive form of heart disease.
